BioCentury | Nov 17, 2020
Management Tracks

Gujrathi leaving as Gossamer CEO; plus Spark, Atlas, Flagship, Talaris

...global head of R&D at Merck KGaA (Xetra:MRK). He will begin his new role on Jan. 1. Talaris Therapeutics Inc....
...raised $100 million in a series A round led by Blackstone Life Sciences. BC Staff Spark Gossamer Atlas Venture Flagship Pioneering Talaris Therapeutics Inc....
BioCentury | Oct 7, 2020
Product Development

Oct. 6 Quick Takes: BARDA whistleblower quits NIH; plus COVID-19 updates from Vir-GSK, BioNTech, Pfizer, $115M B round for Talaris and more

...for collection, receipt, storage, protection, processing, tracking, retrieval, packaging and distribution.  Surveyor, Viking lead Talaris’ megaround Talaris Therapeutics Inc....
BioCentury | Apr 19, 2019
Company News

Emerging company roundup: Kintai, Nocion, Arrakis and more

...named Paul Wotton CEO. The company formerly known as Regenerex LLC announced a new name, Talaris Therapeutics Inc....
...Screening for Antibody Discovery” ). BC Staff Arrakis Therapeutics Inc. insitro Inc. Kintai Therapeutics Inc. Nocion Therapeutics Inc. Obsidian Therapeutics Inc. Phenomic AI Talaris Therapeutics Inc....
BioCentury | Apr 18, 2019
Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

...trial to induce durable immune tolerance in living donor kidney transplant recipients. The company, formerly Regenerex...
...Among 37 evaluable living donor kidney transplant recipients who received FCR001 in the U.S trial, Talaris Therapeutics Inc....
...was senior director, insights and analytics at Radius Health Inc. (NASDAQ:RDUS). Chris Lieu, Staff Writer Novartis AG Regenerex LLC FCR001 Talaris Therapeutics Inc....
BioCentury | Nov 11, 2013
Company News

Regenerex, Novartis, University of Louisville deal

...and royalty payments from Regenerex as part of a September deal between Regenerex and Novartis. Regenerex...
...with Novartis for the biotech's hematopoietic stem cell-based Facilitating Cell Therapy (FCRx) technology, to which Regenerex...
...graft survival without the need for immunosuppression. The university could not be reached for details. Regenerex...
BioCentury | Sep 16, 2013
Company News

Regenerex, Novartis deal

...Regenerex granted Novartis exclusive, worldwide rights and entered a research collaboration deal for Regenerex's hematopoietic stem...
...for use in inherited metabolic storage disorders and hemoglobinopathies. Novartis declined to disclose details, and Regenerex...
...which consists of a cancer antigen-binding domain targeting CD19 linked to CD3-zeta/CD137 immunostimulatory domains. Regenerex...
Items per page:
1 - 6 of 6
BioCentury | Nov 17, 2020
Management Tracks

Gujrathi leaving as Gossamer CEO; plus Spark, Atlas, Flagship, Talaris

...global head of R&D at Merck KGaA (Xetra:MRK). He will begin his new role on Jan. 1. Talaris Therapeutics Inc....
...raised $100 million in a series A round led by Blackstone Life Sciences. BC Staff Spark Gossamer Atlas Venture Flagship Pioneering Talaris Therapeutics Inc....
BioCentury | Oct 7, 2020
Product Development

Oct. 6 Quick Takes: BARDA whistleblower quits NIH; plus COVID-19 updates from Vir-GSK, BioNTech, Pfizer, $115M B round for Talaris and more

...for collection, receipt, storage, protection, processing, tracking, retrieval, packaging and distribution.  Surveyor, Viking lead Talaris’ megaround Talaris Therapeutics Inc....
BioCentury | Apr 19, 2019
Company News

Emerging company roundup: Kintai, Nocion, Arrakis and more

...named Paul Wotton CEO. The company formerly known as Regenerex LLC announced a new name, Talaris Therapeutics Inc....
...Screening for Antibody Discovery” ). BC Staff Arrakis Therapeutics Inc. insitro Inc. Kintai Therapeutics Inc. Nocion Therapeutics Inc. Obsidian Therapeutics Inc. Phenomic AI Talaris Therapeutics Inc....
BioCentury | Apr 18, 2019
Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

...trial to induce durable immune tolerance in living donor kidney transplant recipients. The company, formerly Regenerex...
...Among 37 evaluable living donor kidney transplant recipients who received FCR001 in the U.S trial, Talaris Therapeutics Inc....
...was senior director, insights and analytics at Radius Health Inc. (NASDAQ:RDUS). Chris Lieu, Staff Writer Novartis AG Regenerex LLC FCR001 Talaris Therapeutics Inc....
BioCentury | Nov 11, 2013
Company News

Regenerex, Novartis, University of Louisville deal

...and royalty payments from Regenerex as part of a September deal between Regenerex and Novartis. Regenerex...
...with Novartis for the biotech's hematopoietic stem cell-based Facilitating Cell Therapy (FCRx) technology, to which Regenerex...
...graft survival without the need for immunosuppression. The university could not be reached for details. Regenerex...
BioCentury | Sep 16, 2013
Company News

Regenerex, Novartis deal

...Regenerex granted Novartis exclusive, worldwide rights and entered a research collaboration deal for Regenerex's hematopoietic stem...
...for use in inherited metabolic storage disorders and hemoglobinopathies. Novartis declined to disclose details, and Regenerex...
...which consists of a cancer antigen-binding domain targeting CD19 linked to CD3-zeta/CD137 immunostimulatory domains. Regenerex...
Items per page:
1 - 6 of 6